Urethral dilator
By adopting the multi-specimen dilated capsule group and membranous urethra marker design in the urethra dilator, continuous expansion and depth control of the urethra is achieved, solving the painful problem of multiple insertion and removal in the existing urethra dilation operation, significantly alleviating the patient The pain.
Patent Information
- Application Number
- CN202420368826.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2034-02-28
AI Technical Summary
In urethrascopy, existing urethra dilation operations require multiple insertion and removal of dilators of different specifications, causing pain to the patient.
Design a urethral dilator, which contains multiple dilated capsule groups of different specifications, realizes urethral dilation by injecting fluid into the dilated capsule, and does not need to be removed before dilation is completed, and uses a tubular structure and a cross-shaped injection tube to connect it. Different dilated capsules, and a membrane urethra marking ring is set on the left side of the dilated capsule group to assist in controlling the insertion depth.
The patient's pain is greatly relieved, the continuous expansion of the urethra is achieved, and the expansion size can be adjusted according to the needs of different patients, and the insertion depth can be controlled assisted by the membrane urethra marking ring.
Smart Images

Figure CN221998614U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to a urethral dilator and belongs to the technical field of medical treatment. Background Art
[0002] During urethroscopy, the doctor will insert a mirror through the patient's urethral opening to observe the lesions in the anterior urethra, posterior urethra and bladder. When the patient's urethra is narrow, the patient needs to undergo urethral dilation. The existing urethral dilation operation method is to first use a low-specification urethral dilator, and then change to a larger-specification urethral dilator after a certain period of dilation. For example, first insert an F14 dilator, and then remove the F14 dilator after a certain period of dilation, and then insert an F16 dilator, and then remove the F16 dilator after a certain period of dilation, and insert an F20 dilator until it is expanded to the required size. This requires multiple insertions and removals of the dilator, which causes great pain to the patient. Utility Model Content
[0003] The technical problem to be solved by the utility model is to provide a urethral dilator. The urethral dilator adopts an expansion capsule group connected to the main body. The expansion capsule group includes a plurality of expansion capsules of different specifications. The expansion of the urethra is achieved by injecting liquid into different expansion capsules. It does not need to be removed before the expansion is completed, which greatly reduces the pain of the patient.
[0004] The utility model is realized by the following scheme: a urethral dilator comprises a main body and an expansion capsule group, the main body passes through the expansion capsule group, the main body is provided with an injection port A, an injection port B, an injection port C and an injection port D, the expansion capsule group comprises the expansion capsule A, the expansion capsule B, the expansion capsule C and the expansion capsule D, the injection port A is inside the expansion capsule A, the injection port B is inside the expansion capsule B, the injection port C is inside the expansion capsule C, the injection port D is inside the expansion capsule D, the left end of the main body is connected with an injection tube A, an injection tube B, an injection tube C and an injection tube D, the injection tube A is communicated with the injection port A, the injection tube B is communicated with the injection port B, the injection tube C is communicated with the injection port C, and the injection tube D is communicated with the injection port D.
[0005] The expansion capsule D is inside the expansion capsule C, the expansion capsule C is inside the expansion capsule B, and the expansion capsule B is inside the expansion capsule A.
[0006] The main body is a tubular structure.
[0007] The opening directions of the liquid injection port A, the liquid injection port B, the liquid injection port C and the liquid injection port D are all different.
[0008] The injection tube A, the injection tube B, the injection tube C and the injection tube D are in a cross shape.
[0009] A membrane urethra marker ring is connected to the main body.
[0010] The membranous urethra marker ring is on the left side of the dilation sac group.
[0011] The beneficial effects of the utility model are:
[0012] 1. The utility model adopts a urethral dilator connected to a main body, wherein the dilation capsule group includes a plurality of dilation capsules of different specifications. The urethra is expanded by injecting liquid into different dilation capsules. The urethra does not need to be removed before the expansion is completed, which greatly reduces the pain of the patient.
[0013] 2. The urethral dilator of the utility model is provided with a membrane urethral marking ring, which can assist the doctor in controlling the insertion depth. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The utility model is a front view cross-sectional structural schematic diagram of a urethral dilator.
[0015] Figure 2 It is a schematic diagram of the large-scale three-dimensional structure of a urethral dilator injection tube of the utility model.
[0016] In the figure: 100 is the main body, 101 is the injection port A, 102 is the injection port B, 103 is the injection port C, 104 is the injection port D, 201 is the expansion capsule A, 202 is the expansion capsule B, 203 is the expansion capsule C, 204 is the expansion capsule D, 301 is the injection tube A, 302 is the injection tube B, 303 is the injection tube C, 304 is the injection tube D, and 400 is the membranous urethra marking ring. DETAILED DESCRIPTION
[0017] Combine the following Figure 1 and 2 The utility model is further described, but the protection scope of the utility model is not limited to the described contents.
[0018] Example 1
[0019] A urethral dilator comprises a main body 100 and an expansion capsule group, the main body 100 passes through the expansion capsule group, the main body 100 is a tubular structure, the main body 100 is provided with a liquid injection port A101, a liquid injection port B102, a liquid injection port C103 and a liquid injection port D104, the expansion capsule group comprises expansion capsules A201, expansion capsules B202, expansion capsules C203 and expansion capsules D204, the liquid injection port A101 is in the expansion capsule A201, the liquid injection port B102 is in the expansion capsule B202, the liquid injection port C103 and the liquid injection port D104 are provided, 202, the injection port C103 is in the expansion bag C203, the injection port D104 is in the expansion bag D204, the left end of the main body 100 is connected to the injection tube A301, the injection tube B302, the injection tube C303 and the injection tube D304, the injection tube A301 is connected to the injection port A101, the injection tube B302 is connected to the injection port B102, the injection tube C303 is connected to the injection port C103, and the injection tube D304 is connected to the injection port D104.
[0020] The opening directions of the liquid injection port A101, the liquid injection port B102, the liquid injection port C103 and the liquid injection port D104 are all different, and the liquid injection tubes A301, the liquid injection tubes B302, the liquid injection tubes C303 and the liquid injection tubes D304 are in a cross shape.
[0021] The expansion capsule D204 is inside the expansion capsule C203, the expansion capsule C203 is inside the expansion capsule B202, the expansion capsule B202 is inside the expansion capsule A201, the diameter of the expansion capsule A201 after filling is 6 mm, the diameter of the expansion capsule B202 after filling is 7 mm, the diameter of the expansion capsule C203 after filling is 8 mm, and the diameter of the expansion capsule D204 after filling is 9 mm.
[0022] When in use, the urethral dilator is inserted into the patient's urethra to the required depth, and normal saline is injected into the dilation capsule A201 through the injection port A101. At this time, the expansion size of the urethral dilator is 6mm. After 10 minutes, normal saline is injected into the dilation capsule B202 to expand the size to 7mm. After 10 minutes, normal saline is injected into the dilation capsule C204 to expand the size to 8mm. After 10 minutes, normal saline is injected into the dilation capsule D204 to expand the size to 9mm. After 10 minutes, the urethral dilation is completed.
[0023] There is no need to remove the urethral dilator during the entire dilation process, which greatly reduces the patient's pain.
[0024] Since the urethral conditions of each patient are different, the required expansion size is also different. Different expansion capsule sets can be used according to different expansion requirements.
[0025] Example 2
[0026] In order for the doctor to control the insertion depth, a membrane urethra marker ring 400 is connected to the main body 100, and the membrane urethra marker ring 400 is on the left side of the dilation balloon group.
[0027] Example 3
[0028] A through urination passage is provided in the main body 100, and a urination opening is provided at the right end of the main body 100 to discharge urine during the urethra expansion process.
[0029] Although the technical solutions of the present invention have been described and listed in detail, it should be understood that it is obvious to those skilled in the art to make modifications to the above-mentioned embodiments or adopt equivalent alternatives. These modifications or improvements made without departing from the spirit of the present invention are within the scope of protection required by the present invention.
Claims
1. A urethral dilator, characterized in that: The invention comprises a main body (100) and an expansion capsule group, wherein the main body (100) passes through the expansion capsule group, and the main body (100) is provided with an injection port A (101), an injection port B (102), an injection port C (103) and an injection port D (104), and the expansion capsule group comprises an expansion capsule A (201), an expansion capsule B (202), an expansion capsule C (203) and an expansion capsule D (204), wherein the injection port A (101) is inside the expansion capsule A (201), the injection port B (102) is inside the expansion capsule B (202), and the injection port C (103) is inside the expansion capsule The expansion bag C (203) is inside the expansion bag D (204), and the injection port D (104) is inside the expansion bag D (204). The left end of the main body (100) is connected to the injection tube A (301), the injection tube B (302), the injection tube C (303) and the injection tube D (304). The injection tube A (301) is connected to the injection port A (101), the injection tube B (302) is connected to the injection port B (102), the injection tube C (303) is connected to the injection port C (103), and the injection tube D (304) is connected to the injection port D (104).
2. A urethral dilator according to claim 1, characterized in that: The expansion sac D (204) is inside the expansion sac C (203), the expansion sac C (203) is inside the expansion sac B (202), and the expansion sac B (202) is inside the expansion sac A (201).
3. A urethral dilator according to claim 1, characterized in that: The main body (100) is a tubular structure.
4. A urethral dilator according to claim 1, characterized in that: The opening directions of the liquid injection port A (101), the liquid injection port B (102), the liquid injection port C (103) and the liquid injection port D (104) are all different.
5. A urethral dilator according to claim 1, characterized in that: The injection tube A (301), the injection tube B (302), the injection tube C (303) and the injection tube D (304) are in a cross shape.
6. A urethral dilator according to claim 1, characterized in that: The main body (100) is connected to a membrane urethra marker ring (400).
7. A urethral dilator according to claim 6, characterized in that: The membranous urethra marker ring (400) is on the left side of the dilation sac group.
